Tesamorelin is a research‑grade synthetic analogue of growth hormone‑releasing hormone (GHRH) supplied as a lyophilized powder for investigator‑controlled reconstitution. It stimulates pituitary growth hormone secretion and is used in preclinical and laboratory studies investigating visceral fat reduction, metabolic effects and regenerative processes.
Key Features
- GHRH analogue
- Stimulates endogenous growth hormone release via GHRH receptor activation
- Investigational tool for visceral fat reduction, metabolic health and muscle support
- Supplied lyophilized to allow custom reconstitution and dosing
- Available vial size: 10mg
Product Specifications
- Product name: Tesamorelin 10mg (Purity: 99+% HPLC)
- Category: GHRH analogue / research peptide
- Supplied in: Lyophilized powder in sterile vial + 3ml bac water
- Administration (research/preclinical): Subcutaneous injection (typical)
- Storage (reconstituted): Store at 2–8 °C
Potential Research Applications
- Studies on visceral fat reduction and body composition
- Investigations of GH‑mediated metabolic and anabolic effects
- Preclinical research into aging biology and regenerative outcomes
- Combination studies with exercise, nutrition or other metabolic interventions
Reconstitution & Dosing Guide
Important: The following examples are for laboratory reference only. Validate all calculations, aseptic technique and solvent compatibility with your institutional protocols before use.
Example reconstitution (10 mg vial + 1.0 mL bacteriostatic water)
- Resulting concentration: 10 mg/mL
- Example dosing volumes (U‑100 insulin syringe reference):
- 1.0 mg = 0.10 mL (10 units)
- 1.5 mg = 0.15 mL (15 units)
- 2.0 mg = 0.20 mL (20 units)
Suggested Research Protocol
- Typical investigational dose range reported in experimental contexts: 0.5–2.0 mg per administration
- Common schedule used in research: once daily (Monday–Friday) to support GH release and metabolic endpoints
- Cycle lengths seen in study designs: 8–16 weeks on with 4–8 weeks off; tapering generally not required
- Protocols should be designed and approved by qualified investigators and institutional oversight
Research Insights
- Tesamorelin has been investigated for its capacity to reduce visceral adipose tissue and improve aspects of metabolic health via increased pituitary GH release.
- Effects are often reported within weeks when combined with dietary and exercise interventions; outcomes depend on model, dose and study design.
Possible Observations and Adverse Events (Preclinical/Experimental Context)
- Mild local injection site irritation
- Temporary headache or dizziness (very rare)
Storage, Stability and Handling After Reconstitution
- Reconstituted solutions: store at 2–8 °C and protect from prolonged light exposure
Safety and Handling
- Follow institutional biosafety, handling and waste disposal protocols.
Frequently Asked Questions
Q: Is 0.5 mg a reasonable starting research dose?
A: Many protocols begin conservatively at 0.5–1.0 mg; dose selection should be guided by study objectives and approved by oversight bodies.
Q: Can Tesamorelin be dosed daily?
A: Yes — daily dosing or 5 days a week (often Monday–Friday) is commonly used in experimental designs to support sustained GH release, but schedules should be study‑specific.
Q: When might effects be seen?
A: Changes in visceral fat and body composition may be observable within weeks depending on the experimental model and concurrent interventions.
Legal and Regulatory Notice
By purchasing this product you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical and customs requirements. Liability for misuse is disclaimed.
